Moderna Inc. [NASDAQ: MRNA] jumped around 25.35 points on Friday, while shares priced at $348.83 at the close of the session, up 7.84%. The company report on July 23, 2021 that EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of the Moderna COVID-19 Vaccine in Adolescents (12-17 Years of Age) in the European Union.
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for Moderna’s COVID-19 vaccine (Spikevax) to include adolescents 12 years of age and older. Spikevax is the trade name authorized by the European Medicines Agency (EMA) for the Moderna COVID-19 vaccine.
“The CHMP recommendation of the authorization of our COVID-19 vaccine for use in individuals 12 years of age and older in the European Union is a positive step forward toward authorization of our vaccine in this age group,” said Stéphane Bancel, Chief Executive Officer of Moderna. “As we help to combat the pandemic, we hope to be able to help get adolescents safely back to school this fall.”.
Moderna Inc. stock is now 233.90% up from its year-to-date (YTD) trading value. MRNA Stock saw the intraday high of $349.45 and lowest of $325.17 per share. The company’s 52-week high price is 342.51, which means current price is +237.82% above from all time high which was touched on 07/23/21.
Compared to the average trading volume of 12.32M shares, MRNA reached a trading volume of 23385204 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Moderna Inc. [MRNA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $184.92 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Hold, with their previous recommendation back on July 15, 2021. The new note on the price target was released on February 01, 2021, representing the official price target for Moderna Inc. stock. Previously, the target price had yet another raise to $150, while Morgan Stanley analysts kept a Equal-Weight rating on MRNA stock. On December 16, 2020, analysts increased their price target for MRNA shares from 90 to 150.
The Average True Range (ATR) for Moderna Inc. is set at 18.58, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 47.54. The Price to Book ratio for the last quarter was 36.34, with the Price to Cash per share for the same quarter was set at 20.77. Price to Free Cash Flow for MRNA in the course of the last twelve months was 25.94 with Quick ratio for the last quarter at 1.30.
How has MRNA stock performed recently?
Moderna Inc. [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 21.79. With this latest performance, MRNA shares gained by 64.51% in over the last four-week period, additionally plugging by 166.24% over the last 6 months – not to mention a rise of 363.07% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 85.50, with the RSI for the last a single of trading hit 89.11, and the three-weeks RSI is set at 82.11 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 218.16, while it was recorded at 322.87 for the last single week of trading, and 152.81 for the last 200 days.
Moderna Inc. [MRNA]: Deeper insight into the fundamentals
Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.40.
Earnings analysis for Moderna Inc. [MRNA]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc. go to 16.80%.
Insider trade positions for Moderna Inc. [MRNA]
There are presently around $73,593 million, or 54.50% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: BAILLIE GIFFORD & CO with ownership of 45,337,764, which is approximately 86.481% of the company’s market cap and around 2.50% of the total institutional ownership; BLACKROCK INC., holding 20,803,397 shares of the stock with an approximate value of $7.26 billion in MRNA stocks shares; and FLAGSHIP PIONEERING INC., currently with $7.18 billion in MRNA stock with ownership of nearly -33.333% of the company’s market capitalization.
Positions in Moderna Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 482 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 43,296,650 shares. Additionally, 315 investors decreased positions by around 31,264,880 shares, while 92 investors held positions by with 136,408,783 shares. The mentioned changes placed institutional holdings at 210,970,313 shares, according to the latest SEC report filing. MRNA stock had 182 new institutional investments in for a total of 6,726,886 shares, while 95 institutional investors sold positions of 1,625,071 shares during the same period.